Sign In
Buy COEP
$10.99
+0 (+0%)
At Close: Jul 22, 2026
Coeptis Therapeutics to Present at the Emerging Growth Conference
07:30am, Monday, 04'th Dec 2023
WEXFORD, Pa. , Dec. 4, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms fo
Poster presentation describes the development of SNAP CAR platform technology as a "universal" CAR therapy with the potential to target multiple antigens through combinatorial use of different adaptor
Coeptis Therapeutics Announces $2 Million Private Placement
08:30am, Tuesday, 24'th Oct 2023
WEXFORD, Pa. , Oct. 24, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms f
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology
07:30am, Wednesday, 11'th Oct 2023
Coeptis now has exclusive rights to SNAP-CAR NK and SNAP-CAR T-Cell technology platforms WEXFORD, Pa. , Oct. 11, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "
Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies
09:15am, Monday, 09'th Oct 2023
WEXFORD, Pa. , Oct. 9, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms fo
Poster to be presented by research team from University of Pittsburgh, led by Jason Lohmueller, Ph.D., Assistant Professor of Immunology WEXFORD, Pa.
Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa
07:30am, Wednesday, 27'th Sep 2023
WEXFORD, Pa. , Sept. 27, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms
DVX201, a first-ever allogeneic, cord-blood derived, natural killer (NK) cell therapy, has been administered to 16 patients with no dose limiting toxicities, cytokine release syndrome or infusion toxi
Grants totaling approximately $3.5 million will support Deverra's CAR-NK and engineered myeloid cell programs in hematologic malignancies and solid tumors WEXFORD, Pa. , Sept. 11, 2023 /PRNewswire/ --
Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer
01:00pm, Wednesday, 30'th Aug 2023
Dr. Delaney joins Coeptis after securing exclusive rights from Deverra Therapeutics for its allogeneic immuno-oncology platform and clinical stage programs WEXFORD, Pa. , Aug. 30, 2023 /PRNewswire/ --
Coeptis bolsters pipeline with two Phase 1 clinical stage assets leveraging NK cell therapies in relapsed or refractory acute myeloid leukemia (AML)/high risk MDS and hospitalized respiratory infectio
Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic
08:00am, Tuesday, 01'st Aug 2023
513(g) request will help initiate dialogue with FDA and guide regulatory pathway WEXFORD, Pa. , Aug. 1, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ("Coeptis" or "the Compa
How the Internet Turned Us Into Horrible Investors
11:37am, Wednesday, 03'rd May 2023
What would happen if performance grading suddenly disappeared? No more dreaded annual job reviews
Why Is Coeptis Therapeutics (COEP) Stock Up 14% Today?
08:38am, Monday, 27'th Mar 2023
Coeptis Therapeutics (NASDAQ: COEP ) stock is climbing higher on Monday despite a lack of news from the drug company. Investors searching for the reason why COEP stock is up today won't find much news
This SPAC is merging with an already-public company as sponsors get creative before time runs out
12:54pm, Thursday, 09'th Jun 2022
Many sponsors face challenges as they race the clock to find a target amid regulatory crackdown and waning enthusiasm.
